| Authors: |
Dampier CD; Department of Pediatrics, Emory University, Atlanta, GA.; Aflac Cancer and Blood Disorders Center, Atlanta, GA.; Children's Healthcare of Atlanta, Atlanta, GA., Telen MJ; Division of Hematology, Duke Comprehensive Sickle Cell Center, Duke University Medical Center, Durham, NC., Wun T; Division of Hematology Oncology, UC Davis School of Medicine, Sacramento, CA., Brown RC; Department of Pediatrics, Emory University, Atlanta, GA.; Aflac Cancer and Blood Disorders Center, Atlanta, GA.; Children's Healthcare of Atlanta, Atlanta, GA., Desai P; James Comprehensive Cancer Hospital & Solove Research Institute, The Ohio State University Wexner Medical Center, The Ohio State University, Columbus, OH., El Rassi F; Georgia Comprehensive Sickle Cell Center and Grady Health System, Atlanta, GA.; Department of Medicine, Emory University, Atlanta, GA., Fuh B; East Carolina University Comprehensive Sickle Cell Center, Greenville, NC., Kanter J; Department of Medicine, University of Alabama, Birmingham, AL., Pastore Y; CHU Sainte-Justine, Montreal, QC, Canada.; Department of Pediatrics, University of Montreal, Montreal, QC, Canada., Rothman J; Division of Pediatric Hematology/Oncology, Duke University Medical Center, Durham, NC., Taylor JG; Center for Sickle Cell Disease, Howard University College of Medicine, Washington, DC., Readett D; Pfizer Inc, Collegeville, PA., Sivamurthy KM; Pfizer Inc, Collegeville, PA., Tammara B; Pfizer Inc, Collegeville, PA., Tseng LJ; Pfizer Inc, New York, NY., Lozier JN; GlycoMimetics Inc, Rockville, MD., Thackray H; GlycoMimetics Inc, Rockville, MD., Magnani JL; GlycoMimetics Inc, Rockville, MD., Hassell KL; Division of Hematology, University of Colorado, Aurora, CO. |
